This study was designed to assess the effect of the addition of low-dose spironolactone on blood pressure (BP) in patients with resistant arterial hypertension. Patients with office systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicentre trial. One hundred sixty-one patients in outpatient internal medicine departments of 6 hospitals in the Czech Republic were randomly assigned to receive 25 mg of spironolactone (N = 81) or a placebo (N = 80) once daily as an add-on to their antihypertensive medication, using simple randomization. This study was registered with ClinicalTrials.gov, number NCT00524615. A nalyses were done with 150 patients who finished the follow-up (74 in the spironolactone and 76 in the placebo group). At 8 weeks, BP values were decreased more by spironolactone, with differences in mean fall of SBP of -9.8, -13.0, -10.5, and -9.9 mm Hg (P < 0.001 for all) in daytime, nighttime, and 24-hour ambulatory BP monitoring and in the office. The respective DBP differences were -3.2, -6.4, -3.5, and -3.0 mm Hg (P = 0.013, P < 0.001, P = 0.005, and P = 0.003). Adverse events in both groups were comparable. The office SBP goal <14 mm Hg at 8 weeks was reached in 73% of patients using spironolactone and 41% using placebo (P = 0.001). Spironolactone in patients with resistant arterial hypertension leads to a significant decrease of both SBP and DBP and markedly improves BP control.

From the Department of Internal Medicine 1 Cardiology Faculty of Medicine and Dentistry University Hospital Olomouc and Palacký University Olomouc

Zobrazit více v PubMed

Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403–1419. PubMed

Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 2011; 57:1076–1080. PubMed

Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14:7–12. PubMed PMC

Kumbhani DJ, Steg PG, Cannon CP, et al. REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013; 34:1204–1214. PubMed

Ouzan J, Pérault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15:333–339. PubMed

Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925–930. PubMed

Sharabi Y, Adler E, Shamis A, et al. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006; 19:750–755. PubMed

Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007; 25:891–894. PubMed

Chapman N, Dobson J, Wilson S, et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49:839–845. PubMed

Václavík J, Kociánová E, Táborský M. Use of spironolactone in the treatment of resistant arterial hypertension. Cor Vasa 2011; 53:343–347.

de Souza F, Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010; 55:147–152. PubMed

Rodilla E, Costa JA, Pérez-Lahiguera F, et al. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol 2009; 62:158–166. PubMed

Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, et al. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; 28:2329–2335. PubMed

Association for the Advancement of Medical Instrumentation. American National Standard. Electronic or Automated Sphygmomanometers. Arlington: AAMI; 1993.

Jansen PM, Danser AH, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens 2009; 27:680–691. PubMed

Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) - study protocol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011; 155:143–148. PubMed

Václavík J, Sedlák R, Plachý M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57:1069–1075. PubMed

Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461–470. PubMed

O’Brien E, Waeber B, Parati G, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. Blood pressure measuring devices: recommendations of the European Society of Hypertension. Brit Med J 2001; 322:531–536. PubMed PMC

O’Brien E, Asmar R, Beilin L, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23:697–701. PubMed

Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266–3281. PubMed

Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens 2007; 25:747–750. PubMed

Oxlund CS, Henriksen JE, Tarnow L, et al. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens 2013; 31:2094–2102. PubMed

Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18:50–55. PubMed

Hansen TW, Li Y, Boggia J, et al. Predictive role of the nighttime blood pressure. Hypertension 2011; 57:3–10. PubMed

Batterink J, Stabler SN, Tejani AM, et al. Spironolactone for hypertension. Cochrane Database Syst Rev 2010; 8: CD008169. PubMed

Parthasarathy HK, Ménard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011; 29:980–990. PubMed

Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46:481–487. PubMed

Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2:462–468. PubMed

Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30:418–424. PubMed

Parthasarathy HK, Alhashmi K, McMahon AD, et al. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens 2010; 28:170–177. PubMed

Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54:475–481. PubMed PMC

Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010; 56:824–830. PubMed

Esler MD, Krum H, Sobotka PA, et al. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376:1903–1909. PubMed

Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. J Hypertens 2012; 30:1047–1055. PubMed

Vaclavik J, Sedlak R, Jarkovsky J, et al. The effect of spironolactone in patients with resistant arterial hypertension in relation to baseline blood pressure and secondary causes of hypertension. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157:50–55. PubMed

Vaclavik J, Sedlak R, Jarkovsky J, et al. Effect of spironolactone in patients with resistant arterial hypertension in relation to age and sex: insights from the aspirant trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 158:384–390. PubMed

Bhatt DL, Kandzari DE, O’Neill WW, et al. SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370:1393–1401. PubMed

Pharmacotherapy of arterial hypertension in patients with psoriasis

Zobrazit více v PubMed

ClinicalTrials.gov
NCT00524615